834 Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood

Megan Krumpoch; Huidong Chen; Lia Luus; Michaela Mentzer; Aleksey Molodtsov; Adrian Ray; Vinod Yadav; Matthew Clark; Ian Gerken; Justin Snider; Blaise Lippa; Bruce Rogers; Gerard Bain; Natalia Reszka-Blanco

doi:10.1136/jitc-2022-SITC2022.0834

Article info

Regular and Young Investigator Award Abstracts

Combination Immunotherapies

834 Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood

Free

Authors

Megan Krumpoch Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Huidong Chen Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Lia Luus Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Michaela Mentzer Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Aleksey Molodtsov Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Adrian Ray Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Vinod Yadav Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Matthew Clark Labcorp Drug Development, Ann Arbor, MI, United States PubMed articles Google scholar articles
Ian Gerken Labcorp Drug Development, Ann Arbor, MI, United States PubMed articles Google scholar articles
Justin Snider Labcorp Drug Development, Ann Arbor, MI, United States PubMed articles Google scholar articles
Blaise Lippa Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Bruce Rogers Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Gerard Bain Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles
Natalia Reszka-Blanco Morphic TX, Waltham, MA, United States PubMed articles Google scholar articles

Citation

Krumpoch M, Chen H, Luus L, et al

834 Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0834

Publication history

First published November 7, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password